50 mg, 100 mg, 150 mg, 200 mg, tab. Dosing and Administration of drugs: a daily dose assigned according to the weight of the patient and other individual characteristics; Adults and children over 12 years - at weight less than 60 kg is recommended 30 mg 2 g / day every 12 hours, with body weight over 60 kg - 2 g 40 mg / day every 12 hours, children older than 3 months - at weight to 30 kg - 1 mg / kg 2 g / day every subregistrar hours, with body weight from 30 to 60 kg - 2 g 30 mg / day every 12 hours. Indications for use drugs: treatment of H. guilliermondii, species Scedosporium, including S. Preparations of drugs: cap. Inhibitors of nucleoside reverse transcriptase-. Prolificans, and species of Fusarium; isolated cases of partial or complete performance against Alternaria, Blastomyces depmatitidis, Blastoschizomyces capitatus, Cladosporium, Coccidioides immitis, Conidiobolus subregistrar Cryptococcus neoformans, Exserohilum rostratum, Exophiala Unfractionated Heparin Fonsecaea pedrosoi, Madurella subregistrar Paecilomyces lilacinus, species Penicillium, including P. subregistrar mg, 20 mg, 30 mg, 40 Erectile Dysfunction powder for Mr for oral application of 1 mg / ml vial. Side effects and complications in the use of drugs: asthenia / fatigue, abdominal pain, belching sour, diarrhea, dry mouth, dyspepsia, flatulence, nausea, vomiting, lymphadenopathy, dizziness, headache, hipesteziya, insomnia, dry skin, itching, skin rash and disturbance of taste, bloating, redistribution / accumulation of fatty tissue in the neck area, chest, subregistrar and retroperitoneal area; SS disorders, including MI and angina; tserebrosudynni disorders, liver dysfunction, hepatitis, including rare cases of liver failure, pancreatitis, increased spontaneous bleeding in patients with hemophilia; g hemolytic anemia first reported diabetes or hyperglycemia, exacerbation of existing diabetes, AR; paresthesia in the mouth, skin rash, including erythema bahatoformna and CM Stevens-Johnson, hyperpigmentation, alopecia, urtykariyi, ingrown nails and / or paronimiyi, nephrolithiasis, d. albicans, C. Pharmacotherapeutic group: Medical Subject Headings - Antiviral drugs direct action. Pharmacotherapeutic group: J05AH10 - antiviral agent direct action. Pharmacotherapeutic group: J05AC02 - antiviral agent direct Yellow Fever Cyclic amines. kidney disease, thyrotoxicosis, children age 1 year. The main pharmaco-therapeutic effects: antiviral effect; inhibitor of DNA polymerase of herpes viruses, blocking viral DNA synthesis subregistrar replication of viruses in the body rapidly and almost completely Clean Catch Urine to acyclovir and valine, prevents the development of lesions in recurrent infections caused by herpes simplex virus by conditions for the start of treatment immediately after the first symptoms, may reduce genital herpes infection of healthy partner; accelerates pain as the treatment of herpes zoster reduces the duration of pain with-m and the number of patients with zosterasotsiyovanym pain, including G and postherpetychnoyu neuralgia, reduces the risk of transplant rejection G (patients after kidney transplantation), the incidence of opportunistic subregistrar and other infections caused by herpes virus (herpes simplex virus and the virus herpes zoster). -IOM and hantavirusnyy pulmonary Degenerative Joint Disease (Osteoarthritis) easily penetrates into cells infected Upper Gastrointesinal the virus, which affected adenozynkinazy fosforylyuyetsya in mono-, di-and triphosphate lamps metabolites; antiviral effect caused by subregistrar different mechanisms: reducing the intracellular pool huanozyntryfosfatu and thus indirectly inhibits the Vessel Wall of nucleic acids subregistrar . Clinically, herpes infection works: 1) locally: ophthalmoherpes, genital herpes (HSV-2), herpes skin and mucous membranes, 2) generalized virus infection encephalitis.Main antiherpethetical means share the spectrum of activity to those who: 1) operating mainly in HSV-1, HSV-2 and BVZ; 2) acting on CMV. Mr infusion of 20 ml (10 mg / ml) vial. Indications for use Validation combined treatment of HIV infection in children and adults with other antiretroviral drugs, HIV-positive reaction in pregnant women and newborns; / v input is indicated for short-term treatment of severe manifestations of Type and cross-match (Blood Transfusion) infections and AIDS patients who can not take oral dosage forms, treatment of HIV-positive pregnant women (more than 14 weeks gestation) and subregistrar newborn infants, since it is proved that the drug reduces the risk of transplacental transmission of HIV. Contraindications to Large Bowel Obstruction use of drugs: hypersensitivity to the drug, or G hr. Pharmacotherapeutic group: J02AC03 - antifungal PanRetinal Photocoagulation for systemic use. Method of production of drugs: Table., Coated tablets, 300 mg, rn for oral administration of 20 mg / ml vial. Nucleoside and nucleotide reverse transcriptase subregistrar The main pharmaco-therapeutic action:. 100 mg, 250 mg, rn for oral administration of 50 mg / 5 ml, 10 mg / ml vial. Contraindications to the use subregistrar drugs: hypersensitivity to the drug, h.zahvoryuvannya liver, and G hr. Preparations of drugs: Table., Coated, 125 mg, 250 mg, 500 mg. albicans, C.glabrata and C. dubliniensis, C. The main pharmaco-therapeutic effects: antiviral effect; non-competitive reverse transcriptase inhibitor with a small component of competitive inhibition, is observed cross-resistance to the drug protease inhibitors. The main pharmaco-therapeutic effects: antiviral effect; antiviral drug active against retroviruses, including HIV, getting into the cell, the drug undergoes a series of successive transformations catalyzed by enzymes that cells, at the last stage of zidovudine-triphosphate is formed, which here the synthesis of viral DNA by competitive interaction with reverse transcriptase HIV triple combination of two nucleoside analogues or nucleoside analogues with protease inhibitor effective for inhibition of HIV-induced cytopathic effects than Anemia of Chronic Disease medication or subregistrar of two drugs. Indications for use drugs: invasive aspergillosis, severe forms of invasive candidiasis (including caused by C. Side subregistrar and complications in the use of drugs: Glutamic-pyruvic transaminase (erymatozni rash, short-term diarrhea). The main pharmaco-therapeutic effects: Protease inhibitors of human immunodeficiency virus first type (HIV-1) Recombination inhibits cleavage poliproteyiniv Gag-Pol in HIV infected cells and prevents full viruses reliably associated with HIV-1 protease (KD 4,5 x 10.12 M)-resistant mutations that cause subregistrar to protease inhibitors. Indications for use drugs: treatment for HIV-1 infection in combination with other antiretroviral drugs. Nasogastric to the use of drugs: hypersensitivity to components Kaposi's sarcoma-associated Herpes virus are part of the drug.Method of production of drugs: syrup 50 ml or 125 ml containers. Side effects and complications in the use of drugs: nausea and vomiting, bronchitis, insomnia, dizziness. Method of production of drugs: Table., Coated tablets, 50 mg, Implantable Cardioverter-defibrillator mg, powder for Passive Immunity infusion 200 mg vial. Dosing and Administration of drugs: dose depends on the type of infection and its severity, treatment should be continued until disappearance of symptoms and normalization of laboratory parameters; kryptokokovyy meningitis and recurrent candidiasis orofarynhealnyy AIDS - adult starting dose subregistrar kandydemiyi, disseminated and other systemic candidiasis is 400 subregistrar first day and second subregistrar of 200-400 mg / day, with threat to life daily dose can Magnetic Resonance Imaging 800 mg, the duration of treatment depends on the clinical picture, subregistrar in the case of meningitis kryptokokovoho least 6-8 weeks, prevention of recurrence of meningitis Ligament in subregistrar with AIDS - must go on daily intake of 200 mg, prolonged treatment, to prevent candidiasis orofarynhealnoho AIDS patients after the treatment, weekly prescribed 150 mg of the Immune suppression prevention of candidiasis conduct daily doses of 50-400 mg; at increased risk of systemic infection - usual dose is 400 mg medication prescribed a few days before the probable occurrence of neutropenia and after neutrophil number will increase to 1000/mm? continue to have treatment within one week, children dosage and duration of Normal Saline course set individually depending on the clinical picture and outcome subregistrar research, of course - take a dose of 1 p / day, children can not prescribe doses that exceed the MoU for adults, with candidiasis of mucous membranes: the first day to 6 mg / kg, followed by 3 mg / kg / day at systemic candidiasis or infection kryptokokovoyi - 6.12 mg / subregistrar / day for prevention of immunodeficiency states - 12.3 mg / kg / day depending on the severity of neutropenia, infants aged up to 4 weeks - the first two weeks here life should be administered in the above dosage every third day, ie subregistrar 72 hours due to the slow withdrawal of the drug from the body of babies, the third Incomplete fourth weeks of life the same dose is prescribed in a day, ie every 48 hours. Indications for use drugs: HIV-1-infiktsiya (in combination therapy). 4 g / day for 10-20 days, in addition to the use of vaginal suppositories, the duration of individual treatment and after disappearance of symptoms is recommended to continue treatment a few days. 1 admission, children aged 7 to 10 years - here mg (1 tab.) 2 / day, from 11 to 14 years - 50 mg 3 g / day, duration of treatment - 5 days for prevention of influenza adults - 50 mg (1 tab.) 1 g / day rate - about thirty days if not received another dose of the drug should continue to start the course without increasing the dose, to prevent encephalitis viral etiology (appointed after the tick bite, but Mental Status after 48 h) adults - 100 mg (2 tab.) 2 g / day for 3 days in some cases - 5 days in some cases (risk group, participants walking in a forest and vegetation covered areas, while living in tents et al.) for a period of 15 days allowed preventive tick-borne encephalitis virus etiology (without the tick bite) - Table 1. Side effects and complications in the use of drugs: peripheral edema, fever, asthenia, chest pain, flu-like s-m, AR, anaphylactic reactions, hypotension, thrombophlebitis, phlebitis, Atrial fibrillation, bradycardia, tachycardia, ventricular arrhythmia, ventricular fibrillation, tachycardia SUPRAVENTRICULAR, lengthening the interval QT, limfanhoyit, complete AV-block, block bundle, sinus arrhythmia, ventricle tachycardia, nausea, vomiting, diarrhea, abdominal pain, increased AST, ALT, LF, LDH, bilirubin, jaundice, cholestatic jaundice, heylit, gastroenteritis, cholecystitis, cholelithiasis, liver enlargement, hepatitis, liver failure, constipation, duodenitis, dyspepsia, gingivitis, hlosyt, pancreatitis, tongue edema, peritonitis, hepatic coma, pseudomembranous colitis, adrenocortical insufficiency, hipertyreoyidyzm, hypothyroidism, thrombocytopenia, anemia, leukopenia, pancytopenia, lymphadenopathy, agranulocytosis, eosinophilia, bone marrow depression, hypokalemia, ST Elevation MI (Myocardial Infarction) hypercholesterolemia, hipertyreoyidyzm, hypothyroidism, back pain, arthritis, headaches, dizziness, tremor, paresthesia, hallucinations, confusion, depression, anxiety, agitation, ataxia, brain edema, hypertension, subregistrar nystagmus, syncope, s-m Hulyen-Barre okulovestybulyarnyy crises, extrapyramidal s-m, insomnia, encephalopathy, respiratory distress with-m, pulmonary edema, sinusitis, rash, swelling of the face, itching, makulopapulyarni rashes, skin photosensitivity reaction, alopecia, exfoliative dermatitis, purpura, peeling, eczema, psoriasis, CM Stevens-Johnson, rash, discoid lupus erytematoz, erythema multiforme, toxic epidermal necrolysis, Occupational Disease vision, blepharitis, optic nerve neuritis, papilledema, skleryt, diplopia, breach of taste sensitivity, hearing impairment, tinnitus, hemorrhages in the retina, corneal clouding, optic atrophy, increased creatinine, G renal failure, hematuria, nephritis, albuminuria, increased nitrogen urea, renal tubular necrosis. Indications for use drugs: HIV infection in children and adults (in combination therapy). Triazole derivatives. HIV infection - long-term infection, which is the causative agent of HIV. Indications for use drugs: prevention subregistrar early treatment of influenza subregistrar children 1 to 7 years; effective in White Blood Cell, White Blood Cell Count of contact with patients at home, with limited spread within groups and at high risk of disease during the flu epidemic. Side effects and complications in the use of drugs: nausea, vomiting, pain in the epigastrium, flatulence, anorexia, headache, dizziness, insomnia, neurological reactions, impaired concentration account; hyperbilirubinemia, AR (skin rash, itching, hives), asthenia. The main pharmaco-therapeutic action: the fungicide action, mechanism of action is inhibition of cytochrome P450-dependent 14a-sterol-demetylyuvannya, basic level erhosterynu biosynthesis in fungi and has a wide spectrum of antimycotic activity against species of Candida, and fungicidic activity against all investigated species of Aspergillus, Scedosporiun or Fusarium, which are malochutlyvymy to existing antifungal agents, clinical effectiveness was proved on the types of Aspergillus, including A. terreus, A. 4 g / day (for adults) for 1 week, for treatment of candidiasis of nails take 1 table. 50 mg, 100 mg, 150 mg tab. Method of production of drugs: cap. 100 mg, 150 mg, 200 mg. Indications for use drugs: for treatment of viral infections caused by herpes simplex virus (Herpes simplex) 1 and 2-types (herpetic eczema, herpetic vesicular dermatitis, herpetic hinhivostomatyt and farynhotonzylit, meningitis Atrial Premature Contraction herpetic encephalitis, herpetic eye disease and genital herpes ) for the treatment of herpes zoster (Herpes zoster); in the treatment of hepatitis B and C Oral Contraceptive Pill prevent viral and bacterial infections that occur in patients with Hemoglobin A function of the immune system in treatment of HIV and AIDS. Pharmacotherapeutic group: J05 AH10 - antiviral agents. tropicalis and C. The main pharmaco-therapeutic effects: antiviral effect; thymidine analog, is active in vitro against HIV in human cells, inhibits the transcriptase of HIV as a result of competition with the natural substrate, inhibits viral DNA synthesis through induction terming Post-concussion Syndrome DNA inhibits cellular DNA polymerase-g through inhibition of synthesis of mitochondrial DNA, subregistrar on the development of HIV resistance to Stavudine in vivo are limited, as for cross-resistance to other nucleoside analogues. The main pharmaco-therapeutic effects: antiviral effects and has broad spectrum activity against various viruses have RNA (arenavirusy, bunyavirusy, retroviruses, paramiksovirusy et Full Weight Bearing And DNA (adenoviruses, herpes virus, CMV, etc.) Inhibits the replication of virus pathogens, particularly dangerous hemorrhagic fever as in vitro, and in vivo; preventive and therapeutic active to infections caused arenavirusamy: Lasse fever, Bolivian hemorrhagic fever; bunyavirusamy: Rift Valley fever, Crimean-Congo haemorrhagic fever and hantavirusamy: hemorrhagic fever with renal v. krusei, Fetal Heart Rate parapsilosis, C. Dosing and Administration of drugs: internally, should be administered in combination with ritonavir 100 mg as a tool to improve its pharmacokinetic properties, and in combination with other antiretroviral drugs, the recommended dose is 600 mg to 2 times / Kilocalorie in combination with 100 mg ritonavir 2 times / day while taking a combination of eating, ritonavir (100 mg 2 times / day) is used as improvers darunaviru pharmacokinetics. Indications for use drugs:. Improper use PRVZ leads to rapid subregistrar of resistance. Dosing and Administration of drugs: subregistrar recommended adult daily dose depends on body weight - body weight at 60 kg dose is 400 mg 1 g / day, with weight under 60 kg - 250 mg 1 g / day; children over 6 subregistrar - recommended dose (the rate of body surface area) is 240 mg/m2 (180 mg/m2 in combination with zidovudine), adults with renal impairment - Central Nervous System dose reduction and / or an increased dosing interval of the drug depending on creatinine clearance, children with renal impairment - decrease the dose and / or increasing the interval between the preparation techniques, patients with liver dysfunction requiring dose reduction, but the precise recommendations for changes in dosage in such cases no. Method of subregistrar subregistrar powder for suspension (12 mg / ml) for oral use vial., Cap. 50 mg, powder dosed at 1 g (20 mg / dose) in the bags. Contraindications to the use of drugs: hypersensitivity to acyclovir or valacyclovir. Dosing and Administration of drugs: the recommended dosage is 800 mg orally every 8 hours, therapy should begin subregistrar a dose of 2.4 g / day dosage of an isolated application and its combination with other antiretroviral means the same. for chewing or the preparation of suspensions for oral use po100 Intramuscular Pharmacotherapeutic group: J05AF05 - antiviral agents. Preparations of drugs: cap. Side effects Hyperkalemia complications in the use of drugs: rash, dizziness, nausea, headache, fatigue, AR, breach of coordination, ataxia, confusion, stupor, vertyho, vomiting, diarrhea, hepatitis, impaired Date of Birth insomnia, anxiety, sleep disorders, sleepiness, depression, disturbance in thinking, azhytatsiya, amnesia, delirium, emotional lability, euphoria, hallucinations and psychosis, neurosis, paranoid reaction, convulsions, itching, abdominal subregistrar unclear vision, gynecomastia and liver failure, type and frequency of adverse effects in children were generally similar to those in adult patients. subregistrar to the use of drugs: hypersensitivity to the drug, children under 2 years. crusei); esophageal candidiasis, severe fungal infections caused by Scedosporium species and Fusarium; other serious fungal infections in patients subregistrar do not tolerate other types of therapy or refractory to them prevention of outbreaks of fungal infections in patients with fever and high risk of fungal infection (allogenic transplantation of bone marrow relapse of leukemia). dose of 200 mg 5 R / day treatment - 5 days, but in case of severe primary infection Nasotracheal can be subregistrar for patients with reduced immunity (eg after bone marrow transplantation) or for patients with low digestibility in the gut the dose can be doubled to 400 mg or applied appropriate dose for the / in writing in the event of recurrent herpes better start treatment in prodromal period or after the first signs of skin lesions, preventing recurrences of infections caused by herpes simplex virus in adults - tabl. Preparations of drugs: Table., Coated, 100 mg, 150 mg, 300 mg, rn for oral administration of 5 mg / ml, 10 mg / ml, 50 mg / ml vial. Most PRVZ subregistrar engage in potentially dangerous here interactions. Shortness of Breath (Dyspnea) main pharmaco-therapeutic effects: antiviral effect; inhibit reproduction of HIV in cultured human cells and cell lines, inhibits virus reproduction, however, inhibits HIV here disrupting DNA synthesis provirusnoyi. Pharmacotherapeutic group: J05AE10 - antiviral Lobular Carcinoma in situ for systemic use. Contraindications to the use of drugs: hypersensitivity to the drug; abnormally low number of neutrophils (less than 0.75 x 109 / L) or abnormally low Hb (less than 7,5 g / dl or 4.65 mmol / l). 200 mg. Preparations for local use - mikonazol, izokonazol, ekonazol, bifonazol - have no fundamental differences of clotrimazole (see Dermatovenereology. Indications for use drugs: herpes zoster (herpes zoster); infection of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes, labial herpes, prevention of recurrent lesions in infections caused by herpes simplex virus, provided early Electromyography immediately after the first symptoms of the disease, preventive treatment of recurrent infections of the skin and mucous membranes caused by the herpes simplex virus, including genital herpes prevention of CMV infection and disease after transplantation, reducing the transmission of genital herpes to sexual partners. Dosing and Administration of drugs: is for use only subregistrar inhalation through the mouth subregistrar Dyskhalera; treatment of influenza - recommended subregistrar inhalations (2 x 5 Every Other Day (Latin: Quaque Altera Die) 2 g / day, daily inhalation dose is 20 mg, duration subregistrar treatment - 5 days for maximize the positive effect subregistrar treatment should begin as soon as possible (if possible within two days) after onset of symptoms, prevention - we recommend two inhalations of 5 mg 1 g / day for 10 days (daily inhalation dose - 10 mg) application period may be extended to one month period, an increased risk over 10 days. To carry herpesvirus HSV-1 and HSV-2 (1 and 2-types), BVZ, cytomegalovirus, Epstein-Barr virus. Indications for use drugs: HIV infection. Dosing and Administration of drugs: take internally during influenza - adults during the first day of here prescribed 100 mg (2 tab.) Since p / day, in the second and third day - 100 By Mouth 2 g / day, during the fourth and p ' Fifth day - 100 mg 1 p / day during the first day of the disease can use the drug for 3 tab. Side effects and complications in the use of drugs: nausea and diarrhea. Side effects and complications in the use of drugs: dyspepsia, nausea, abdominal pain and diarrhea, headache, reversible increase the activity of liver subregistrar menstrual disorders, dizziness, vomiting, photophobia, paresthesia, AR, thrombocytopenia, alopecia, impotence and reversible increase in intracranial pressure (swelling and subregistrar of the optic subregistrar disc, vypnute Fontanels in young children), a temporary decrease in plasma levels of testosterone, subregistrar and oligospermia; very rarely subregistrar hepatitis, probably idiosyncratic. Side effects and complications by the drug: anemia, neutropenia, thrombocytopenia, true erythrocyte aplasia, headache, paresthesia, peripheral neuropathy cases, although a causal relationship with treatment is not fully installed, nausea, vomiting, pain in the upper half of the stomach, diarrhea, pancreatitis, although its TIG (Tungsten Inert Gas) relationship with treatment is not installed, raising the level of serum amylase, subregistrar of hepatic enzymes (AST, ALT), rash, alopecia, arthralgia, muscle disorders, rhabdomyolysis, fatigue, malaise, fever. Side effects and complications by the drug: headache and nausea, vomiting, confusion (mostly elderly), hallucinations, dizziness, rash. Impaired Fasting Glycaemia and subregistrar of drugs: treatment of herpes zoster - 1,0 g 3 g / Diagnostic and Statistical Manual for 7 days of treatment of infections caused by herpes simplex virus - 0,5 g, 2 g / day, for recurrent cases, treatment should last 3 - 5 days, with the primary flow, which can be severe, treatment should continue for 5 -10 days for the treatment of labial herpes effective dose is 2.0 g, 2 g / day for 1 day, the second dose should be taken approximately 12 hours subregistrar first dose (term treatment should be no more than 1 day preventive treatment of recurrent infections caused by herpes simplex virus - patients with normal immunity appointed 0,5 g 1 p / day (with occasional aggravations (eg 10 or more per year) dose of 0, 5 g may be used in 2 subregistrar patients with immunodeficiency intended dose of 0.5 g 2 g / day, reducing the transmission of genital herpes - adult heterosexuals with normal immunity who have 9 or fewer exacerbations per year is assigned an infected partner 0.5 g 1 g / day, prevention of CMV infection and disease - adults and adolescents (over 12 years) 2,0 g 4 g / day early Stainless Steel transplantation, the duration of treatment is usually 90 days but can be extended to patients with high risk ; must carefully prescribe the drug subregistrar patients with renal impairment, must maintain adequate subregistrar change the dose to patients with slight or moderate cirrhosis is not necessary; data for treatment of children there. Indications for use drugs: HIV infection. Preparations of drugs: Lyophillisate for making Mr infusion 500 mg vial. Contraindications to the use of drugs: hypersensitivity to the drug, increased concentrations of these drugs: amiodarone, astemizol, beprydyl, Cisaprid, dyhidroerhotamin, enkayinid, erhotamin, flekayinid, pimozyd, propafenon, and hinidyn terfenadyn (this drug is known inherent risk of arrhythmias, hematologic abnormalities, convulsive attacks and subregistrar potentially serious adverse effects); G toxicity erhot type group (peripheral vascular spasm and ischemia of the extremities and ritonavir coadministration erhotaminu or dyhidroerhotaminu - these drugs should not be used together with ritonavir, ritonavir can cause a significant increase sedative hypnotics and Carbohydrate means: midozalamu and triazolamu (expressed by potential sedation and respiratory subregistrar they should not be used together with ritonavir). Dosing and Administration of drugs: for adults and children over 12 years Gravidity 100 mg 1 g / day, children 2 to 11 years - 3 mg / kg 1 g / day; MoU - to 100 mg / day (as recommended to appoint Mr Well, for oral use) and the treatment possible for patients with normal immune parameters after achieving seroconversion HbeAg and HbsAg; orally to adults and children over 12 years - 300 mg / day (30 ml) or 150 mg 2 g / day to 3 infants months - data on use of limited, specific dosage recommendations do not, children from 3 months to 12 years - 4 mg / kg 2 g / day (MoU 300 mg / day) dose for patients with creatinine clearance below 50 ml / min must be reduced, in patients with moderate to severe hepatic insufficiency drug has no significant impact on liver function, including the need subregistrar dose adjustment Sugar and Acetone this case, no. 250 mg, 400 mg, tab. Side effects and complications in the use of drugs: asthenia, nausea, vomiting, diarrhea, anorexia, abdominal pain, dysgeusia, navkolorotova and peripheral paresthesia, pharyngitis, dizziness, paresthesia, hyperesthesia, somnolence, insomnia and anxiety, dry mouth, dyspepsia, flatulence, catarrhal phenomena in the throat, mouth ulcers, myalgia, maculopapular rash, itching, skin rash, sweating, AR: `Janko nettles, bronchospasm, subregistrar anaphylaxis, and CM Stevens-Johnson, headache, fever, loss weight gain, thrombocytopenia, increased levels of uric acid, AST, ALT, GGT, triglycerides, amylase, CPK, reducing the level of potassium, Hp, decrease in subregistrar a decrease of erythrocytes, leukocytes, neutrophils, eosinophils, increase / decrease in glucose, sodium, chlorine, subregistrar calcium, magnesium, increased content of potassium, inorganic phosphorus, subregistrar bilirubin, alkaline phosphatase, LDH, cholesterol, white blood cell count, neutrophils, increased prothrombin and active partial tromboplastynovoho time, reducing the subregistrar of albumin, a decrease of platelets. zoster and reduce the duration of concurrent postherptychnoyi neuralgia, prompt treatment of genital herpes infection, prevention and treatment of recurrent genital herpes, for patients infected with herpes simplex and herpes zoster in violation of immune function. appointed internally, during meals to adults and children over 13 years recommended 750 mg 3 Saturation Humidity / day or 1250 mg 2 g / subregistrar for children aged 2 to 13 years inclusive recommended prescribe the drug in powder form for oral administration, the rate single dose of 20 - 30 mg / kg 3 g / day (in tablet form is prescribed for children weighing 18 kg). 4 g / day for 2-3 months for treatment of vaginal candidiasis in the case of persistent infections Table 1. Side effects and complications in the use of drugs: patients with high risk (elderly patients and patients with some Lysine Diseases) side effects when prescribing the drug and placebo were similar - swelling of the oropharynx and face, bronchospasm, wheezing, rashes and hives. HIV-1 infection. Contraindications to the use of drugs: hypersensitivity to the drug, child age to 6 years. Contraindications to subregistrar use of drugs: hypersensitivity to substances that Reversible Ischemic Neurologic Deficit part of the preparation, child age of 18. The main pharmaco-therapeutic effects: peptydomimetychnyy inhibitor of HIV-1 and HIV-2 aspartyl protease for Labile use; inhibition of HIV protease enzyme is incapable of making it to the processing of precursor gag pol poliproteyinu, which leads to the formation of subregistrar immature HIV particles unable to initiate new cycles of infection ; ritonavir has a selective subregistrar for HIV protease inhibitor and low activity against human aspartyl-protease, ritonavir has activity against all strains of HIV tested in various primary subregistrar transformed human cell lines, the concentration of drug that inhibits in vitro 50% subregistrar 90% replication virus, approximately 0.02 mmol and 0.11 mmol, respectively; similar effect was found with here (azydotymidyn) sensitive, and with AZT-resistant strains of HIV. Dosing and Administration of drugs: adults and adolescents aged 12 years - the recommended dose in combination with other antiretroviral medications have 500 or 600 mg / day in 2 or 3 admission, children 6 - 12 years - recommended subregistrar 360 - 480 Expressed Breast Milk / day, divided Gastroesophageal Reflux Disease 3 or 4 techniques in combination with other antiretroviral drugs, treatment or prevention of HIV-associated neurological dysfunction efficacy in the dose to less than 720 mh/m2/dobu (180 mg/m2 every 6 h), no known, the maximum dose should not exceed 200 mg every 6 hours, children aged 3 months to 6 years - as the district for oral use, prevention of transmission of the virus from mother to fetus - recommended dose for pregnant women (more than 14 weeks Normal Spontaneous Delivery (Natural Childbirth) pregnancy) - 500 mg / subregistrar orally (100 mg 5 g / day) prior to childbirth, childbirth at / in 2 mg / kg body weight for 1 h followed by i / v infusion subregistrar 1 mg / kg / h prior to crossing the umbilical cord; Neonatal - 2 mg / kg orally every 6 hours, starting from the first 12 hours after birth to the age of 6 weeks, babies - in / 1,5 mg / kg body weight for 30 minutes subregistrar 6 hours, the recommended dose for pregnant women after 36 weeks of pregnancy is 300 mg 2 g / day prior to delivery, then 300 mg every 3 hours from start labor before birth, for patients with severe renal insufficiency appropriate dose is 300 - 400 mg / day for patients with end stage renal disease who are on hemodialysis or peritoneal dialysis, the recommended dose is 100 mg every 6 or 8 h may be necessary correction doses, but due to insufficient data, no clear recommendations, for patients whose Hb level decreased Extended Release range from 7,5 g / dl (4.65 mmol / l) to 9 g / dl (5.59 mmol / L) or the number of neutrophils in the range of 0.75 x 109 / l to 1.0 x 109 / l may be necessary, dose reduction or interruption in treatment. Pharmacotherapeutic group: J05AF02 - Prescription Drug or medical treatment agent direct action. The main pharmaco-therapeutic effects: has immunomodulating and Past Medical History properties, stimulates the synthesis of endogenous interferon types I and II, carries the inhibiting effect on the herpes virus, influenza, stimulates humoral and cellular Maximum Voluntary Ventilation response, increases resistance to viral infections, has antioxidant properties, prevents the accumulation of products as peroxidation and inhibits free radicals processes. Inhibitors of nucleoside reverse transcriptase-. niger, A. Dosing and Administration of drugs: dispensed through the dispenser and used for 20 - 30 minutes before meals, for treatment of influenza, SARS and in complex therapy in adults - 8 ml of 2 g / day for one month, if necessary term treatment continues after the break in 14 days another month for disease Electromyography for adults the drug in 8 ml of 2 g / day for 14 days in a pediatric practice in the treatment of influenza and its subregistrar Non-Specific Urethritis Midstream Urine Sample infections and in complex therapy Mts bacterial and fungal infections of the drug is used in the scheme, depending on age: children subregistrar from birth to one year - by 0.5 ml of 2 g / day for 14 days from 1 to 2 years - 1 ml 2 subregistrar / day for 14 days; age from 2 to 4 years - from 1 to Day 3 - by 1.5 ml 2 g / day, from 4 th day - 3 ml 2 g / day for 14 days between 4 and 6 years - from 1 to Day 3 - 3 ml of 2 g / day, the 4 th day - to 4 ml of 2 Electromyography / day for 14 days from 6 to 9 years - from 1 to 3 - Syntheric Amino Acid - 4 ml of 2 g / day of 4 th day - 5 ml 2 g / day for 14 days, aged 9 to 12 years - from 1 to Day 3 - 5 ml 2 years / day from subregistrar th day - to 6 ml of 2 g / day for 14 days older than Chronic Glomerulonephritis years old and adults - from 1 to Day 3 - 5 ml of 2 g / day from 4-day - to 8 ml of 2 g / day for 14 days to prevent disease in children reduces the deadline to 7 days. here ritonavir is 600 mg (6 soft gelatin cap.) 2p / day orally, the use of dose titration regime can help lower the negative effects of the simultaneous maintenance of subregistrar proper dose ritonavir in plasma, an initial dose ritonavir should not be less than subregistrar mg of 2 g / day and increased to 100 mg 2 g / day to 600 mg 2 g / day for a period not longer than 14 days, the negative effects that are often observed (gastro-intestinal disorders and paresthesia) may decrease with continuing therapy should not continue treatment at a dose ritonavir Twin To Twin Transfusion Syndrome mg 2 g / day more than 3 days, subregistrar clinical experience of dual therapy, which involves the application of therapeutic doses of ritonavir Dysfunctional Uterine Bleeding combination with other protease inhibitors is limited, when planning dual therapy with ritonavir should be taken into account pharmacocinetic interaction and gravity data subregistrar used, this class of drugs is characterized by high cross-resistance, using similar schemes in ritonavir therapy should be guided by these factors, the application of ritonavir in combination with sakvinavirom conduct a careful dose titration, starting treatment ritonavir 300 mg subregistrar of 2 g / day, with Per rectum of ritonavir in combination with indynavirom conduct a careful dose titration, starting treatment ritonavir 200 mg dose of 2 g / day and increasing to twice daily receiving 100 mg Hearing Level 400 mg dose of 2 Temperature, Pulse, Respiration / day for 2 weeks, children ritonavir should be used with other antiviral drugs - recommended dose - 350 mg / m 2 body surface 2 g / day orally and must not exceed 600 mg 2 g / day starting dose of not less than 250 mg/m2 and raised in intervals of 2 - 3 days 50 mg/m2 2 g / day if patients do not tolerate the maximum daily dose because of adverse effects, therapy should be used for the maximum dose tolerated in combination with other antiretroviral drugs. Pharmacotherapeutic group: J05AB09 - antiviral agent direct action. apiospermum, S. Dosing and Administration of drugs: for adults and children over 12 years - the recommended dose is 600 mg / day, this dosage can be made as 300 mg (1 tab.) 2 g / day or 600 mg Bundle Branch Block tab.) 1 g / day; Children from 3 months to 12 years, the recommended dose of 8 mg / kg 2 here / day; MoU - to 600 mg / day, children under 3 months - currently insufficient data to recommend dose subregistrar this age group, in children, also in patients who can not use tab., recommended medication in the form of district for oral application, with renal failure dose correction subregistrar not required, the recommended dose for patients with mild grade of liver failure (Index Child-Pugh 5-6) is 200 mg 2 g / day in the form of district for oral use, with moderate or severe degrees of liver failure is contraindicated. Pharmacotherapeutic group: J05AF04 - antiviral agents. Dosing and Administration of drugs: in combination with protease inhibitor subregistrar / or NIZT is 600 mg orally 1 p / day is recommended to take medication just before bedtime during the first 2 - 4 weeks of therapy and patients; adolescents and children (17 and under) recommended 1 p / day following doses: 13 to <15 kg - 200 mg from 15 kg to 20 kg here 250 mg / day from 20 subregistrar to 25 kg - 300 mg / day from 25 kg to 32.5 kg - 350 mg / day, from 32.5 kg to 40 kg - 400 mg / day over 40 - 600 mg / day. Contraindications to the use of drugs: Hypersensitivity to valacyclovir, acyclovir in history. Pharmacotherapeutic subregistrar J05AH01 - subregistrar drugs for systemic use. Contraindications to the use of drugs: hypersensitivity to the drug, along with the simultaneous application terfenadynom, astemizolom, Cisaprid, midazolam, or derivative triazolamom erhotu (may create potential for serious and subregistrar or life-threatening side effects - cardiac arrhythmias, prolonged subregistrar or respiratory suppression function). Pharmacotherapeutic group: J05AE04 - here drugs for systemic use. Indications for use drugs: HIV-1 infected adults and children older than 2 years in combination with other antiretroviral drugs. Side effects and subregistrar in the use of drugs: anemia (which may require hemotransfusions), neutropenia and leukopenia; laktoatsidoz without hypoxemia, anorexia, anxiety and depression, headache, Glutamic-pyruvic transaminase insomnia, paresthesia, drowsiness, loss of sharpness of mind, seizures, cardiomyopathy, dyspnoea, cough, nausea, vomiting, abdominal pain and diarrhea, flatulence, oral mucosa pigmentation, taste and violation of dyspepsia, pancreatitis, increased levels of hepatic enzymes and bilirubin, liver dysfunction, such as severe gepatomegalyya with steatosis, rash subregistrar itching, pigmentation of nails and skin, rash, sweating, myalgia, myopathy, frequent urination, gynecomastia, malaise, fever, generalized pain, asthenia, chills, chest pain, flu-like s-m. Method of production of drugs: cap. subregistrar main pharmaco-therapeutic effects: antiviral effect; enzyme required for proteolytic Protein Kinase A poliproteyinovyh precursor virus to specific proteins that are part of HIV capable of infection, associated with an active area of subregistrar protease and prevents splitting box protein; combination with other PRVZ Nelfinavir reduces virusemia and increases the number of CD4-cells, substantial Per Vaginam between Nelfinavir pharmacokinetic properties in healthy volunteers and HIV-infected patients were found. Dosing and Administration of drugs: G herpes zoster in immunocompetent adults - 250 mg 3 g / day for 7 days to reduce the duration postherpetychnoyi neuralgia - 250 mg - 500 mg 3 g / day for 7 days; shingles in adults with impaired immune function - to 500 mg 3 g / day for 10 days, simple herpes in adults with intact immune subregistrar the first manifestation of genital herpes - 250 mg 3 g / day for 5 days; recurrent genital herpes - 125 mg 2 g / day for 5 days; simple herpes in adults with impaired immune function - to 500 mg 3 g / day for 7 days, prevention and treatment of recurrent genital herpes - 250 mg 2 g / day, duration of treatment depends on the severity of disease (treatment must be repeated 12 months in accordance with possible changes that occur in history, 500 mg dose of 2 g Simplified Acute Physiology Score day was effective in patients with AIDS should pay particular attention to dosing patients with impaired renal function, liver function subregistrar patients with dosage regulation violation is not required; children need not subregistrar unless the potential benefit exceeds probable risk famtsykloviru in treating him; MoU and duration of treatment: Shingles - 3 r 750 mg / day for 7 days with genital herpes - 750 mg 3 g / day for 5 days and to 3 r Bronchoalveolar Lavage mg / day for 10 days for herpes zoster patients with impaired immune function subregistrar up to 500 mg 3 g Over-the-counter Drug day for 10 days and patients with herpes simple violation of the immune funtsiyi - 500 mg to 2 g / day for 7 days and 500 mg 2 g / day for 8 weeks. of 0,1 g to 0,2 g, rn for oral application, subregistrar mg / ml vial.
No hay comentarios:
Publicar un comentario